IL6 and melanoma: Interestingly, preliminary results presented at the ESMO Congress 2021 from an ongoing Phase II clinical trial in 41 patients with unresectable melanoma treated with a combination of ipilimumab, nivolumab and anti-IL-6 antibodies reported an encouraging 60% response rate.34